SRRK · NASDAQ · Biotechnology

Scholar Rock

Develops anti-myostatin antibodies for spinal muscular atrophy and other neuromuscular diseases.

$57.80
After-hours close0.00 (0.00%)
At close$57.80(−2.46%)
DateEstimateReportedSurprise
Nov 2026−$0.87
Aug 2026−$0.84−$0.84+0.1%
May 2026−$0.82−$0.83−1.2%
Mar 2026−$0.88−$0.88+0.3%
Nov 2025−$0.84−$0.90−7.8%

The latest year is open to everyone — the 34 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Feb 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Aug 2021
May 2021
Mar 2021
Nov 2020
Aug 2020
May 2020
Mar 2020
Nov 2019
Aug 2019
May 2019
Mar 2019
Nov 2018
Aug 2018
May 2018
Mar 2018
Sep 2017
Jun 2017
Mar 2017
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Nov 13, 2026−$0.87$75.0K
Aug 6, 2026−$0.84−$0.84+0.1%$70.0K$0−100.0%
May 7, 2026−$0.82−$0.83−1.2%$5.0M
Mar 3, 2026−$0.88−$0.88+0.3%$1.8M
Nov 14, 2025−$0.84−$0.90−7.8%$50.0K

The latest year is open to everyone — the 34 quarters behind it read with an account.

Sign in
Aug 6, 2025
May 14, 2025
Feb 27, 2025
Nov 12, 2024
Aug 8, 2024
May 7, 2024
Mar 19, 2024
Nov 7, 2023
Aug 9, 2023
May 9, 2023
Mar 7, 2023
Nov 14, 2022
Aug 8, 2022
May 16, 2022
Mar 7, 2022
Nov 9, 2021
Aug 10, 2021
May 13, 2021
Mar 9, 2021
Nov 9, 2020
Aug 7, 2020
May 7, 2020
Mar 12, 2020
Nov 12, 2019
Aug 14, 2019
May 14, 2019
Mar 18, 2019
Nov 8, 2018
Aug 8, 2018
May 24, 2018
Mar 31, 2018
Sep 30, 2017
Jun 30, 2017
Mar 31, 2017